Ask AI
ProCE Banner Series

A Post-JSMO Update on Novel Antibody-Drug Conjugates and Other Agents Targeting HER3 in NSCLC

Join us for a live webinar on novel agents targeting HER3 for the treatment of patients with NSCLC. Experts on NSCLC will explore the therapeutic relevance of HER3 in EGFR-mutated NSCLC and report on recent and ongoing clinical trials of ADCs and other HER3-targeted agents, including new data presented at the 2023 Japanese Society of Medical Oncology Annual Meeting.

  AMA
Credits Available

1.0

Who Should Attend

Medical oncologists and other healthcare providers who care for patients with lung cancer.

All Events

A Post-JSMO Update on Novel Antibody-Drug Conjugates and Other Agents Targeting HER3 in NSCLC

Past Events

April

06

2023

7:00 AM - 8:00 AM Eastern Time (ET)

Virtual

Topics

A Post-JSMO Update on Novel Antibody-Drug Conjugates and Other Agents Targeting HER3 in NSCLC

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact meetings@clinicaloptions.com prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners to integrate the most recent and emerging data on HER3-targeting agents into NSCLC treatment paradigms.

Target Audience
This program is intended for medical oncologists and other healthcare providers who care for patients with lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate the biologic rationale for targeting HER3 and its role in the resistance to EGFR-directed therapies
  • Appraise new and emerging clinical trial data assessing HER3-targeting agents in NSCLC
  • Describe to colleagues the therapeutic rationale for HER3-targeting and TKI combination therapy in EGFR-mutated NSCLC
  • Select patients with NSCLC who may benefit from ongoing clinical trials evaluating HER3-directed therapies based on tumor characteristics, previous treatment, and patient characteristics and preferences

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by an educational grant from Daiichi Sankyo, Inc.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191